Hypertension is a major disease in the black populations of sub-Saharan Africa and the USA. The prevalence of hypertension varies from 1-30% in the adult population. Differences in blood pressure (BP) between black and white patients have been documented. In this review genetic, endocrine and environmental characteristics, renal physiology and cardiac function are reviewed. Racial differences in renal physiology and socio-economic status seem to account for BP differences. Black hypertensive patients in sub-Saharan
Introduction
A World Health Organisation analysis showed that the prevalence of hypertension in developing countries varied from 1% in some African countries to more than 30% in Brazil. 1 Hypertension is common in the urban black population of Africa.
2 Our agecorrected prevalence studies showed that in the adult population of Durban, hypertension (WHO criteria) was highest in urban Zulus (25%), intermediate in whites (17.2%) and lowest in ethnically Indian people (14.2%) ( Table 1) . Throughout subSaharan Africa there is a difference in the prevalence of hypertension between the urban and rural black populations. Blood pressure (BP) assumes much more importance with increasing age. 3 In a large USA study the prevalence of hypertension was evaluated between 1988 and 1991. The Africa are prone to cerebral haemorrhage, malignant hypertension leading to uraemia and congestive heart failure, whereas coronary artery disease is relatively uncommon. Responses to antihypertensive drugs like the beta-blockers and the angiotensin-converting enzyme (ACE) inhibitors are poor unless these agents are combined with a thiazide diuretic. Black hypertensive patients respond best to diuretics, vasodilators or calcium channel blockers. A profiled approach to the treatment of hypertension in black patients is suggested.
National Health and Nutritional Survey (NHANES)
showed that urban black men have a higher prevalence of hypertension compared to urban black females, white males and white females. Thus even in the USA, black people have a far higher prevalence of hypertension compared to the Caucasian population. 4 The prevalence of hypertension in black people in the West Indies and in the USA is higher than those in any part of sub-Saharan Africa. This may be because African Americans having been accultured for 300 years, whereas urban Zulus have been accultured only since the turn of the 20th century. It is possible that BP differences in the time since acculturation may explain the BP differences between African Americans, West Indians, Nigerians and urban Zulus. 3 Mortality statistics from six developing countries for 35 to 74-year-olds showed a downward trend in mortality from hypertension and cardiovascular diseases in most countries. In spite of the current low prevalence of hypertension in some countries, the total number of hypertensive subjects in the developing world is high, and a cost-analysis of possible antihypertensive drug treatment indicates that developing countries cannot afford the same treatment as developed countries.
1 Hypertension occurs at an earlier age in African Americans compared with whites. 5 The higher prevalence of hypertension in black subjects, particularly in women under 40 years, probably explains the younger age group of hypertensive patients at autopsy. 6, 7 In South Africa, we have found that women between the ages of 35 and 40 years have a higher prevalence of hypertension than men. 3 
Determinant factors in hypertension in black people
Genetic factors, personal characteristics, autonomic nervous system function, cardiac function, and various environmental factors have been examined in hypertensive black subjects and compared and contrasted with hypertensive whites. Black hypertensive subjects have higher plasma sodium and lower plasma potassium concentrations than normotensives. 8 In the South African black population, red cell magnesium and serum levels of potassium, magnesium and calcium were found to be significantly lower in black hypertensive subjects compared with whites. 9 There are also overt differences in potassium transport, which suggest that black people have a more limited capacity to exchange intracellular potassium and that a higher percentage of this exchange is dependent upon oubain-sensitive mechanisms. 10 We have found that lymphocyte intracellular sodium concentrations were significantly higher in hypertensive, compared with normotensive, Zulus.
11 Black subjects excrete sodium loads more slowly and have a markedly lower rate of urinary kallikrein excretion. 12 Renin is lower in black people and does not increase in response to sodium and volume depletion. [13] [14] [15] [16] The distribution curve of plasma renin in black Americans is not 'normal' but rather logarithmic, in contrast to the curve found in whites. 13 We have found that rural Zulus have higher plasma renin activity (PRA) compared to urban Zulus. This suggests that the cause of a low PRA may not be genetic. 17 However, there was no correlation between PRA and urinary sodium, which suggests that dietary sodium was not a factor. 17 There was no correlation between PRA and aldosterone in hypertensive urban Zulus, which suggests a defect in the renin-aldosterone system in these patients. 17, 18 The lack of stimulation of PRA by natriuresis with furosemide confirmed a hyporesponsive renin-angiotensin system in hypertensive urban Zulus. 17 A difference in salivary Na-K ratios between white and black patients with low renin essential hypertension has been noted 19 but daily sodium intake in black South Africans (assessed on the basis of urinary sodium) was similar to that seen in typical Western diets. 17, 20 Grim et al 21 have hypothesised that the increased prevalence of salt-sensitive hypertension in African Americans resulted in part from natural selection during slave transport. A potassium deficient diet may play a role in the aetiology of hypertension in South Africans. 17 White patients have higher levels of plasma dopamine ␤-hydrolase than black patients, and these are associated with lability of BP in hypertensive, but not in normotensive patients. This excess of sympathetic neuronal activity is not sufficient to produce sustained hypertension. 22 Black/white differences in the reactivity to stressors such as the cold pressor test were identified by Schwab et al 23 and have since been confirmed. 24, 25 Hypertensive black subjects show a greater sensitivity to the pressure effects of noradrenaline and this is enhanced by a high-sodium diet. 26 The possible relationship between skin colour and BP has been studied in two cross-sectional studies, one in Charleston 27 and the other in Detroit 28 in the USA. The studies show a direct relationship between skin colour and BP. However, a study of 72 black hospital patients showed that the presence of Duffy red cell proteins, a measure of 'whiteness', was unrelated to elevated BP. 29 Possibly, the studies were confounded by lower social class, which is associated with a greater prevalence of hypertension in black subjects.
The first study to demonstrate familial aggregation of hypertension in black people was that of Miall et al in Jamaica. 30 Obesity is an important cause of hypertension, especially in the urban black women of sub-Saharan Africa. It is more common in urban than in rural Zulu women. 31 In the Hypertension Detection and Follow-up Programme in the USA of 160 000 patients, differences in the prevalence of hypertension in black and white subjects were examined on the basis of education. The subjects of the lower socio-economic group had a higher prevalence of hypertension. They also had a lower level of education. 32 For the same level of education, the prevalence of hypertension in whites was lower than in blacks. The same can be stated of the black subjects in Durban: hypertension was more common in those who married, had lower socio-economic status, poor living conditions, large families, and had less involvement in community life. Alcohol, gambling and lack of sleep contributed to the higher prevalence of hypertension in black subjects. 3 In Los Angeles, USA, Campese et al 33 found that the bulk of whites exhibit a salt-resistant state and the majority of the blacks have a salt-sensitive state. When they were subjected to a low sodium diet the mean arterial pressure, glomerular filtration rate, the renal blood flow, and filtration fraction were similar. When they were challenged with a high sodium intake the BP in the salt-sensitive state (black subjects) was higher than that of the salt-resistant state. During the high sodium intake, glomerular filtration rate was unchanged but renal blood flow rose in the salt-resistant patients but fell in the salt-sensitive patients. As a result, calculated filtration fraction, renal vascular resistance and glomerular pressure all increased in the salt-resistant patients during the high-sodium intake. Campese et al 33 concluded that the rise in filtration fraction and intraglomerular pressure during high sodium intake in the salt-sensitive group might be partially responsible for the greater propensity of renal failure in hypertensive African Americans. The Multiple Risk Factor Intervention Trial (MRFIT) study demonstrated that black people had a higher serum creatinine level for the same level of BP than white subjects. 34 From the therapeutic perspective it is important to consider drugs that reduce renal vascular resistance and glomerular pressure such as calcium channel blockers (CCB).
Black patients whose haemodynamic and fluid status are similar to those of their white counterparts tend to have lower heart rates and greater responsiveness to intravascular volume. 35 Changes in peripheral resistance associated with hypertensive heart disease may start in young black men before elevated BP occurs. Burke et al 36 in a study of over 500 black and white children from a population sample in Bogalusa, Louisiana, USA, found that black boys between the ages of 12 and 22 years showed, on average, increasing levels of peripheral resistance, whereas white boys and girls of the same age, as well as black girls, showed declining peripheral resistance. Adult black subjects with mild hypertension have as much as a two-fold greater prevalence of left ventricular hypertrophy on echocardiography when compared with matched white subjects. 37 Thus, qualitative differences exist between black and white people in respect of the cardiac adaptive process to systemic hypertension. Hypertension is commonly associated with cerebral and aortic atheroma, but coronary heart disease (CHD) is rare in sub-Saharan Africa. Congestive heart failure is common. 6, 38 In contrast in the USA, CHD is common in the African Americans. 39 Malignant hypertension is common in the black people of sub-Saharan Africa and is an important cause of end-stage renal failure. 3 Serum cholesterol concentration is lower and serum high-density lipoprotein is higher in the black compared with the Indian and white people of Durban. 
Varying responses to antihypertensive agents in black subjects

Thiazide diuretics
These are effective antihypertensive agents in black hypertensive patients and studies suggest that they cause a greater decrease in BP in blacks than in whites. 41, 42 The better hypotensive response in black hypertensive patients is probably due to the fact that, in comparison with whites, more black patients have an expanded intracellular volume and low 
Reserpine or rauwolfia extracts
Reserpine or rauwolfia extracts offer the advantage of low cost, once daily administration. Side effects like nasal congestion or depression are minimal provided the dosage of reserpine does not exceed 0.1 mg once daily. Reserpine combined with hydrochlorothiazide is as effective as sotalol with hydrochlorothiazide in black patients. 43 In developing countries where the cost of therapy is important, it may be preferable to use a combination of reserpine and hydrochlorothiazide as baseline drugs in hypertension.
Beta-blockers
There are numerous studies that have shown that beta-blockers are no more effective than placebo in black people. Comparative studies between white and black subjects have shown that white and Indian hypertensive patients respond better to betablockers than black hypertensive patients. Available evidence suggests that beta-blockers with sympathomimetic activity produce better hypotensive results than beta-blockers with cardioselectivity. 44 Betablockers when combined with a thiazide diuretic produce an appreciable hypotensive response in black hypertensive patients. 45 The reason why betablockers do not act effectively in black hypertensive patients will therefore be understood only when we know how they produce their hypotensive effect. Simple pharmacokinetic metabolism and excretion of propranolol and pindolol in black subjects do not differ from those in whites. 46 Racial differences in the antihypertensive response to propranolol were determined in black and white subjects by studying propranolol enantiomer pharmacokinetics and protein binding. The authors concluded that inbound L-propranolol concentrations probably do not explain the clinically observed response to propranolol. They felt that the racial differences in apparent oral clearance could be due to variations in the hepatic metabolism of propranolol. 47 Renin classification does not appear to be instrumental in the initial selection of diuretics or beta-blockers in the therapy of black hypertensives, but diuresis is more effective. 48 Warren and O'Connor 49 proposed that racial (black/white) differences in clinical severity, haemodynamic profile and response to therapy of essential hypertension may be mediated largely by the vasodilatory and natriuretic renal kallikrein-kinin system. They felt that deficiency in the kallikrein-kinin renal vasodilatory system may explain many of the unique features of essential hypertension in at least some black people, especially older subjects with low PRA. Antihypertensive agents like propranolol, which decrease urinary kallikrein excretion may not be effective in all black subjects. Conversely, if a drug like a thiazide diuretic increases urinary kallikrein in black people, it may have a special advantage in this group of patients.
49
Labetalol and carvedilol
These antihypertensive agents block ␣ 1 , ␤ 1 and ␣ 2 adrenergic receptors. They may be more effective than non-selective beta-blockers in black patients. 50 A study of the efficacy of labetalol and propranolol in black and white hypertensive patients showed that while the hypotensive response to propranolol was better in white than in black patients, labetalol was effective in lowering standing and supine systolic and diastolic BPs in both black and white people. 51 We have shown that carvedilol, a new non-cardioselective, vasodilating ␤-adrenoceptor blocker, without intrinsic sympathetic activity is an effective agent for treating hypertension in black patients.
52
Calcium antagonists
Data have shown that black patients, who are prone to a low PRA, respond to calcium channel blockers (CCB). Fadoyami et al, 53 Moser et al, 54 Leary and Asmal, 55 and M'Buyamba-Kabangu et al, 56 have shown a good response to CCB in black hypertensive patients. Leary and Asmal in an open study, found that black hypertensive patients responded significantly better to verapamil than white patients. 55 Cruickshank et al 57 found, in their study on the treatment of hypertension in black compared with white non-insulin-dependent diabetics, that beta-blockers are not effective in treating hypertension in black diabetics. Verapamil was effective although less so than in white patients. The authors conclude that, as yet, no ideal monotherapy exists for hypertension in black diabetic patients. 57 Materson et al 58 found in a randomised doubleblind study of 1292 men with a diastolic BP of 95-109 mm Hg that diltiazem ranked first for younger whites and atenolol for older whites. The patients were randomised after a placebo washout period to receive placebo or one of the six drugs: hydrochlorothiazide (12.5-50 mg per day), atenolol (25-100 mg per day), captopril (25-100 mg per day), clonidine (0.2-0.6 mg per day), a sustained-release preparation of diltiazem (120-360 mg per day), or prazosin (4 -20 mg per day). 58 CCBs may also have a natriuretic effect and thus lower the BP. A further additive hypotensive effect is achieved when CCBs are combined with a diuretic in black patients.
Angiotensin-converting enzyme (ACE) inhibitors
Studies with ACE inhibitors have shown that in black patients the response is poor. However the response is the same as whites when ACE inhibitors are combined with a low-dose diuretic. 44 ACE inhibitors can be effective in black hypertensive patients but in higher doses compared to white and Indian peoples. 59 
Angiotensin II receptor blockers
There is only limited data on the response to angiotensin II (AT 1 ) receptor antagonists in hypertensive blacks. Analysis of the responses in the sub-group or black patients (n = 10-17/study) confirmed that losartan did lower BP in black patients. The magnitude of the fall in black patients appears to be less than in the non-black patients. [60] [61] [62] McIntyre et al 63 stated that on the basis of present information, there is no justification in limiting or restricting losartan to any ethnic group. They felt that a further definitive study on the influences of race on the response to losartan would be justified in the future after marketing. 63 Data on the newer AT 1 receptor antagonists like candesartan, irbesartan, or valsartan and their efficacy in black hypertensive patients are few in a number of patients.
Elderly black hypertensive patients
The data of Materson et al 58 on elderly patients showed that the best antihypertensive response occurred with diltiazem, followed by hydrochlorothiazide, clonidine and prazosin. Atenolol was only slightly better than placebo and captopril was worse than placebo.
58
Diabetic black hypertensive patients ACE inhibitors combined with a small dosage of a thiazide diuretic, for example hydrochlorothiazide 12.5 mg daily, is the treatment of choice. Suitable alternative antihypertensive agents are CCB or ␣-adrenergic blocking agents like prazosin or doxazosin.
Black hypertensive patients with renal disease
The incidence of end-stage renal disease (ESRD) is increasing at the rate of 8-10% per year and poses a major national health problem in the USA. 64 In 1998 nearly 300 000 persons in the USA either underwent dialysis or received a renal transplant for ESRD. Hypertension was found to be the underlying cause in 29% of these patients, second only to diabetes. In black subjects, hypertension was found to be the most common cause of ESRD. 65 This is in contrast to the trend from two major complications of hypertension, myocardial infarction and stroke, both of which decreased in incidence by about 25% in the same decade. 66, 67 In South Africa, a developing country, the number of patients on the registry of the South African Dialysis and Transplantation group was 7331 patients in 1994. Hypertension as a cause of ESRD accounted for 35% in black subjects. 68 The ultimate goal is to prevent renal failure or slow its progression. ACE inhibitors may be more effective than beta-blockers in slowing renal progression. 69 The dihydropyridine CCBs like nifedipine are not as effective as the non-dihydropyridine like verapamil or diltiazem in decreasing proteinuria. 70 In animal experiments co-administration of an ACE inhibitor and a CCB, verapamil, caused a more marked reduction in glomerulosclerosis and this was seen in the stroke-prone spontaneously hypertensive rat model even at non-antihypertensive doses. 71 In human diabetic nephropathy at least, proteinuria (measured as a surrogate marker of the illness) was lowered more effectively by the combination of an ACE inhibitor and a CCB than either drug used as monotherapy despite a similar fall in BP. 72 The renoprotective role of diuretics, ␣-adrenergic blockers, and direct vasodilation is unclear, owing to inadequate data. Long-term controlled studies are needed to assess whether these agents can increase the glomerular filtration rate and promote or fail to arrest glomerulosclerosis in the long run.
The strategies for slowing progressive renal failure in patients with hypertension include early detection of hypertensive renal damage. Small elevations of serum creatinine reflect significant losses in glomerular filtration rate. Evaluation should include urinalysis to detect proteinuria or haematuria and possibly renal sonography to exclude lower urinary tract obstruction. Reversible causes of renal failure should always be sought and excluded. The sixth Report of the JNC Committee (1997) recommends that BP should be controlled to 130/85 mm Hg or lower (125/75 mm Hg) in patients with proteinuria in excess of 1 gram per 24 hours-with whatever antihypertensive therapy is necessary. 73 The recommendation of the sixth JNC Report states that the most important action is to lower BP. 73 All classes of antihypertensive drugs are effective and, in most cases, multiple antihypertensive drugs may be needed. Good results have been achieved with ACE inhibitors in patients with type 1 diabetic nephropathy, in patients with proteinuria greater than 1 gram per 24 hours and in patients with renal insufficiency. Consequently, patients with hypertension who have renal insufficiency should receive, unless contraindicated, an ACE inhibitor, in most cases, along with a diuretic, to control hypertension and to slow progressive renal failure. In patients with a creatinine level of 265.2 mol/l or greater, ACE inhibitors should be used with caution.
Thiazide diuretics are not effective in patients 
Conclusion
Black hypertensive patients respond well to thiazide diuretics, CCB, vasodilators like prazosin, doxazosin, or labetalol (combination of a non-selective ␤-adrenergic blocker and an ␣-␤ blocker). It is suggested that in black hypertensive patients a thiazide diuretic should be routinely added should a betablocker or an ACE inhibitor be used. This is summarised in Table 4 . However, in spite of the effective drug therapy available for hypertensive patients in general, economic and social considerations continue to influence the lower rate of detection, treatment and control of hypertension in the black population of the USA with regard to the cost-benefit ratio. We should be cognisant that thiazide diuretics become the baseline therapy of hypertension. 74, 75 We should be aware of the special needs of black patients when initiating therapy. As yet there is no ideal monotherapy in black hypertensive patients. An ideal antihypertensive drug should have not only natriuretic effects, but also the capability to reduce vascular resistance. 76 Whereas the stepped-care treatment of hypertension is widely used, it has become appropriate to consider an individualised patient profile in the treatment of hypertension. 77 Race should constitute an added criterion when an antihypertensive agent is chosen. 44, 73, 78, 79 
